0001104659-23-078771.txt : 20230706 0001104659-23-078771.hdr.sgml : 20230706 20230706164207 ACCESSION NUMBER: 0001104659-23-078771 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230629 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230706 DATE AS OF CHANGE: 20230706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gardiner Healthcare Acquisitions Corp. CENTRAL INDEX KEY: 0001858912 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 862899992 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41185 FILM NUMBER: 231074127 BUSINESS ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 BUSINESS PHONE: 216-633-6708 MAIL ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 8-K 1 tm2320673d1_8k.htm FORM 8-K
0001858912 false 0001858912 2023-06-29 2023-06-29 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-06-29 2023-06-29 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-06-29 2023-06-29 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-06-29 2023-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 29, 2023

 

 

GARDINER HEALTHCARE ACQUISITIONS CORP.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   001-41185   86-2899992
(State or other jurisdiction of
incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)

 

3107 Warrington Road
Shaker Heights, Ohio		   44120
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (216) 633-6708

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on
which registered
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant   GDNRU   The Nasdaq Stock Market LLC
Shares of common stock, par value $0.0001 per share   GDNR   The Nasdaq Stock Market LLC
Redeemable warrants   GDNRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Cancellation and Release of Promissory Notes

 

On June 29, 2023, Gardiner Healthcare Acquisitions Corp. (the “Company”), Gardiner Healthcare Holdings, LLC (“Gardiner Sponsor”, together with Company the “Borrowers” and each a “Borrower”) and the Lenders (as defined below), entered into a Cancellation and Release Agreement (the “Cancellation and Release Agreement”) pursuant to which each Borrower and Lender agreed that in consideration for the Lenders receiving membership units in Gardiner Founder LLC, a Delaware limited liability company (“Gardiner Founder”), which is the parent of Gardiner Sponsor, the sum of the aggregate outstanding principal, any accrued interest, and any other fees due to each Lender and all other payment obligations and liabilities under the promissory notes from Borrower to each Lender (each a “Promissory Note”, and collectively, the “Promissory Notes”), were cancelled in full without any payment required by the Borrower to the Lender and the Promissory Notes were automatically terminated and of no further force and effect.

 

The Promissory Notes terminated pursuant to the Cancellation and Release Agreement were as follows: (i) Promissory Note dated April 26, 2023, from the Company to Seisun Capital PTY LTD (“Seisun Capital”) for a principal sum of $75,000; (ii) Promissory Note dated April 27, 2023, from the Company to Guy Spriggs Trust 12/16 (“Spriggs”) for a principal sum of $200,000; (iii) Promissory Note dated February 22, 2023, from the Company to Kent Rinker (“Rinker”) for a principal sum of $50,000; (iv) Promissory Note dated February 24, 2023, from the Company to Greg Sukenik (“Sukenik”) for a principal sum of $25,000; (v) Promissory Note dated April 28, 2023, from the Company to Virginia Stack (“Stack”) for a principal sum of $75,000; (vi) Promissory Note dated January 1, 2020, from Gardiner Founder to Moss Ridge Pty Ltd. (“Moss Ridge”) for a principal sum of $300,000; (vii) Promissory Note dated March 23, 2023, from the Company to Moss Ridge for a principal sum of $534,723; (viii) Promissory Note dated March 31, 2023, from the Company to Moss Ridge for a principal sum of $167,000; (ix) Promissory Note dated April 17, 2023, from the Company to Moss Ridge for a principal sum of $30,000; (x) Promissory Note dated March 24, 2023, from the Company to Gardiner Warrant Holdings LLC (“Gardiner Warrant”) for a principal sum of $14,190; and (xi) Promissory Note dated March 24, 2023, from the Company to Sera Australia Pty Ltd (“Sera”, together with Seisun Capital, Spriggs, Rinker, Sukenik, Stack, Moss Ridge and Gardiner Warrant, the “Lenders”, and each a “Lender”) for a principal sum of $14,636.

 

A copy of the Cancellation and Release Agreement is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing description of the Cancellation and Release Agreement is qualified in its entirely by reference thereto.

 

 

 

 

Item 1.02. Termination of a Material Definitive Agreement.

 

The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02.

 

Item 8.01. Other Events.

 

Transfer Back of Interest and Forfeiture of Rights

 

On June 29, 2023, the Company, Gardiner Sponsor, Gardiner Founder, and Janelle Anderson and Dave Jenkins (each individual a “Provider”, and collectively, the “Providers”), among other parties, entered into a letter agreement pursuant to which the Providers transferred their membership interests in Gardiner Sponsor, which corresponded to a ratable number of shares of common stock, par value $0.0001 per share, of the Company back to Gardiner Sponsor in consideration for an interest in Gardiner Founder and in furtherance of the foregoing, agreed to forfeit any and all rights in Gardiner Sponsor, including without limitation any rights in the event the Company completes a business combination and any and all rights in any assets of Gardiner Sponsor.

 

Item 9.01. Financial Statements and Exhibits

 

(c) Exhibits:

 

Exhibit No.   Description
10.1   Cancellation and Release Agreement, dated June 29, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GARDINER HEALTHCARE AcquisitionS Corp.
   
  By: /s/ Marc F. Pelletier
    Name: Marc F. Pelletier
    Title: Chief Executive Officer
   
Date: July 6, 2023  

 

 

 

 EX-10.1 2 tm2320673d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

Certain identified information marked with “[***]” has been omitted from this document because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

 

CANCELLATION AND RELEASE AGREEMENT

 

RELATING TO

GARDINER HEALTHCARE ACQUISITIONS CORP. AND

GARDINER HEALTHCARE HOLDINGS, LLC

 

This Cancellation and Release Agreement (this “Agreement”), is entered into as of June 29, 2023 (the “Effective Date”), by and between each of the persons identified on the lender signature pages attached hereto (each a “Lender” and, collectively, the “Lenders”), on the one-hand, and Gardiner Healthcare Holdings, LLC (“Gardiner Sponsor”) and Gardiner Healthcare Acquisitions Corp. (the “SPAC”), as the borrower entities identified on Exhibit A hereto, and on the applicable borrower signature pages attached hereto (each, a “Borrower” and, collectively, the “Borrowers”, and together with the Lenders, the “Parties”).

 

WHEREAS, under one of more Promissory Note(s) identified on Exhibit A (the “Promissory Note(s)(s)”), each Lender has loans outstanding to one or both of the Borrowers in the principal amount(s) set forth on Exhibit A (the “Loan(s)”);

 

WHEREAS, Gardiner Founder LLC, a Delaware limited liability company (“Founder”), which is the parent of Gardiner Sponsor, intends to enter into a Class A Unit Purchase Agreement, dated on or about the Effective Date, with each of the Lenders (each in such capacity, a “Purchaser” and, collectively, the “Purchasers”) and the other parties thereto (the “Purchase Agreement”) pursuant to which the Founder will sell and transfer to the Purchasers membership units of Founder; and

 

WHEREAS, relation to the Purchase Agreement and the contemporaneous amendment and restatement of the Founder’s limited liability operating agreement the Parties are required to cause this Agreement to be executed and delivered;

 

NOW, THEREFORE, in consideration of the premises set out above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1.Payment. Each Lender and each Borrower hereby agree that the sum of the aggregate outstanding principal, any accrued interest, and any other fees due to the Lender and all other payment obligations and liabilities under the Promissory Note(s) from the Borrower to the Lender as of the Effective Date is as set forth in Exhibit A.

 

2.Cancellation of Loan and Termination of Promissory Note(s). Each Lender and each Borrower hereby agree that the sum of the aggregate outstanding principal, any accrued interest, and any other fees due to the Lender and all other payment obligations and liabilities under the Promissory Note(s) from the Borrower to the Lender as of the Effective Date is the full amount set forth on Exhibit A (the “Cancellation Amount”), it being agreed that no portion of any such Promissory Note has been repaid. The Parties hereby agree that as of the Effective Date the Cancellation Amount shall be cancelled in full without any payment required by the Borrower to the Lender and the Promissory Note(s) shall be automatically terminated and of no further force and effect.

 

 

 

 

3.Mutual Release. As of the Effective Date, each Party, on behalf of itself and each of its Related Parties, does hereby unconditionally and irrevocably release, waive and forever discharge the other Parties and each of its Related Parties (collectively, the “Released Parties”), of and from any and all claims, actions, causes of action, suits, debts, liens, contracts, agreements, promises, commitments, demands, charges, damages, awards, assessments, losses, costs, expenses (including attorneys’ fees and costs), and other liabilities and obligations that such Party or any of its Related Parties may now or henceforth have against the Released Parties, of any nature or kind, known or unknown, suspected or unsuspected, from whatever cause, action, omission, or other matter or circumstance, from the beginning of time to and through the Effective Date, solely to the extent arising out of or relating to the Promissory Note(s) or the related loans. A Party’s “Related Parties” means such Party’s past, present and future parents, subsidiaries, affiliates, employees, officers, directors, shareholders, members, agents, representatives, successors, and assigns.

 

4.Satisfaction and Accord. It is each Party’s intention that this Agreement shall be effective as a full and final accord and satisfactory release of the Promissory Note(s) and related loan(s), subject to such Purchasers receipt of units of Founder as set forth in the Purchase Agreement. Each Party acknowledges that such Party is aware that such Party may hereafter discover claims or facts in addition or different from those such Party now knows or believes to be true with respect to the matters released herein. Nevertheless, it is the intention of each Party to fully, finally and forever settle and release all such matters, and all claims relative thereto, which do now exist, may exist, or heretofore have existed arising out of or relating to the Promissory Note(s) and related loan(s). In furtherance of such intention, this Agreement shall be and remain in effect as a full and complete general release of all such matters, notwithstanding the discovery or existence of any additional or different claims or facts relative thereto.

 

5.Waiver. Each Party acknowledges that the applicable laws of many states provide substantially the following: “A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” Each Party acknowledges that such provisions are designed to protect a party from waiving claims which it does not know exist or may exist. Nonetheless, each Party agrees that, as of the Effective Date, such Party shall be deemed to waive any such provision.

 

6.Administrative Claims; Litigation. Each Party (a) expressly represents, warrants and covenants not to sue the Released Parties to enforce any charge, claim or cause of action released pursuant to this Agreement, (b) participate, assist, or cooperate in any such proceeding, or (c) encourage, assist and/or solicit any third party to institute any such proceeding. This covenant not to bring or maintain any action in law or equity shall be subject to specific enforcement and the Released Parties, or any of them, shall have standing to bring any such action for specific enforcement. This covenant does not apply to any suits or other proceedings to enforce the provisions of this Agreement. In any suit to enforce this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees and costs.

 

- 2 -

 

 

7.COUNSEL.

 

(a)EACH PARTY HAS CAREFULLY READ AND FULLY UNDERSTANDS ALL OF THE PROVISIONS AND EFFECT OF THIS AGREEMENT. EACH PARTY HAS FULL AUTHORITY TO ENTER INTO THIS RELEASE AND TO BE BOUND BY IT. EACH PARTY IS VOLUNTARILY ENTERING INTO THIS RELEASE FREE OF ANY DURESS OR COERCION. EACH PARTY HAS HAD THE OPPORTUNITY TO CONSULT LEGAL COUNSEL OF SUCH PARTY’S OWN CHOOSING WITH RESPECT TO THE EXECUTION AND LEGAL EFFECT OF THIS AGREEMENT.

 

(b)The SPAC has selected Reed Smith LLP (“SPAC Counsel”) as its legal counsel and has requested the assistance of SPAC Counsel in relation to the preparation of this Agreement and ancillary documents for the purpose of facilitating the recapitalization of the SPAC. The Parties acknowledge and agree that SPAC Counsel does not represent any of the Parties, except SPAC, with respect to this Agreement or the recapitalization of the Company in the absence of a clear and explicit agreement to such effect between a Party, as the case may be, and SPAC Counsel (and then only to the extent specifically set forth in that agreement), and that, in the absence of any such agreement, SPAC Counsel, to the fullest extent permitted by applicable law, shall owe no duties to any Party (except SPAC) with respect to this Agreement, any ancillary documents, or the subject matter hereof and thereof. In furtherance of the foregoing, each Party hereby acknowledges and agrees that SPAC Counsel has helped prepare this Agreement and any ancillary documents only in its capacity as counsel to the SPAC to facilitate a recapitalization of the SPAC through Gardiner Sponsor and Founder. The Parties acknowledge and agree that they have been previously advised as to the scope of SPAC Counsel’s representation and of the fact that SPAC Counsel does not represent any of them (except SPAC) in any capacity in relation to the subject matter of this Agreement or any of the ancillary documents. Each Party acknowledges that SPAC Counsel assisted in the preparation of the limited liability company operating agreement of both Gardiner Sponsor and Founder in relation to the SPAC’s initial public offering of securities. Furthermore, the Parties hereby acknowledge and agree that they have been advised that they are entitled to retain advisors, including legal, tax and financial advisors, in relation to their review and execution of this Agreement and all ancillary documents. The Parties acknowledge and agree that, in the event any dispute or controversy arises between the Parties, on the one hand, and the SPAC (or an Affiliate of the SPAC that SPAC Counsel represents), on the other hand, SPAC Counsel may represent either the SPAC or any Affiliate of the SPAC, or both, in any such dispute or controversy to the extent permitted by the applicable rules of professional conduct in any jurisdiction, and each Party hereby consents to such representation. Each Party further acknowledges and agrees that, whether or not SPAC Counsel has in the past represented such Party with respect to other matters, SPAC Counsel has not represented the interests of any Party, except SPAC, in the preparation and negotiation of this Agreement. SPAC Counsel is an express third party beneficiary of this Section 7(b).

 

- 3 -

 

 

8.Severability. If any one or more of the provisions contained in this Agreement, or the application thereof in any circumstance, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired, unless the provisions held invalid, illegal or unenforceable shall substantially impair the benefits of the remaining provisions of this Agreement. The parties hereto further agree to replace such invalid, illegal or unenforceable provision of this Agreement with a valid, legal and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid, illegal or unenforceable provision.

 

9.Governing Law. This Agreement and any certificates delivered pursuant hereto shall be governed by and construed in accordance with the laws of the State of Delaware without reference to the choice of law principles thereof. Each Party hereby agrees and consents to be subject to the exclusive jurisdiction of the United States District Court in Delaware and, in the absence of such federal jurisdiction, the Parties consent to be subject to the exclusive jurisdiction of any Delaware state court located and hereby waive the right to assert the lack of personal or subject matter jurisdiction or improper venue in connection with any such suit, action or other proceeding. In furtherance of the foregoing, each of the Parties (a) waives the defense of inconvenient forum, (b) agrees not to commence any suit, action or other proceeding arising out of this Agreement or any transactions contemplated hereby other than in any such court, and (c) agrees that a final judgment in any such suit, action or other proceeding shall be conclusive and may be enforced in other jurisdictions by suit or judgment or in any other manner provided by law. THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHT SUCH PARTIES MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY SUIT OR ACTION ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HEREBY CERTIFIES THAT NEITHER THE OTHER PARTY NOR ANY OF ITS REPRESENTATIVES HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT IT WOULD NOT SEEK TO ENFORCE THIS WAIVER OF RIGHT TO JURY TRIAL. FURTHER, EACH PARTY ACKNOWLEDGES THAT THE OTHER PARTY RELIED ON THIS WAIVER OF RIGHT TO JURY TRIAL AS A MATERIAL INDUCEMENT TO ENTER INTO THIS AGREEMENT.

 

10.Further Assurances and Cooperation. In connection with this Agreement and the transactions contemplated hereby, each Party shall execute and deliver any additional documents and instruments and perform any additional acts as may be necessary or appropriate and reasonably requested by the other Parties to effectuate and perform the provisions of this Agreement and those transactions. Unless otherwise provided, no consent or approval provided for in this Agreement may be unreasonably withheld or delayed.

 

- 4 -

 

 

11.Counterparts. This Agreement may be executed in any number of counterparts, each of which, when so executed, shall be deemed to be an original, and all such counterparts shall together constitute but one and the same agreement. Counterparts may be delivered via facsimile, electronic mail or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[Signature Page Follows]

 

- 5 -

 

 

IN WITNESS WHEREOF, each Party has executed and delivered this Agreement as of the date first above written.

 

BORROWER:
   
 Gardiner Healthcare Holdings, LLC
   
 By:/s/ Marc F. Pelletier
 Name: Marc F. Pelletier
 Title: Managing Member

 

BORROWER:
   
 Gardiner Healthcare Acquisitions Corp.
   
 By:/s/ Marc F. Pelletier
 Name: Marc F. Pelletier
 Title: Chairman & Chief Executive Officer

 

[Signature Page to Cancellation and Release Agreement]

 

- 6 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Moss Ridge Pty Ltd  
Name of Lender  
   
/s/ Chris Camarsh   
Signature of authorized signatory  
   
Chris Camarsh  
Name of authorized signatory  
   
CIO  
Title of authorized signatory  

 

- 7 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Gardiner Warrant Holdings LLC  
Name of Lender  
   
/s/ Marc Pelletier  
Signature of authorized signatory  
   

Marc Pelletier

  
Name of authorized signatory  
   

Managing Member

  
Title of authorized signatory  

 

- 8 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Seisun Capital PTY LTD  
Name of Lender  
   
/s/ Chris Camarsh   
Signature of authorized signatory  
   
Chris Camarsh  
Name of authorized signatory  
   
CIO  
Title of authorized signatory  

 

[Signature Page to Cancellation and Release Agreement] 

 

- 9 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Sera Australia PTY LTD ATF Serani Hybrid Trust  
Name of Lender  
   
/s/ Anthony Julian  
Signature of authorized signatory  
   
Anthony Julian  
Name of authorized signatory  
   
Director  
Title of authorized signatory  

 

- 10 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Guy Spriggs Trust 12/16  
Name of Lender  
   
/s/ Guy Spriggs  
Signature of authorized signatory  
   
Guy Spriggs  
Name of authorized signatory  

 

Owner    
Title of authorized signatory

 

- 11 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Virginia (Gerald) Stack  
Name of Lender  
   
/s/ Virginia Stack  
Signature of Lender  

 

- 12 -

 

 

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Kent Rinker  
Name of Lender  
   
/s/ Kent Rinker  
Signature of Lender  

 

- 13 -

 

  

COUNTERPART SIGNATURE PAGE

TO

CANCELLATION AND RELEASE AGREEMENT

 

IN WITNESS WHEREOF, the Lender listed below has entered into this Cancellation and Release Agreement as of the Effective Date.

 

Greg Sukenik  
Name of Lender  
   
/s/ Greg Sukenik  
Signature of Lender  

 

- 14 -

 

 

Exhibit A

 

List of Lenders, Borrowers, Promissory Notes (including dates and amounts)

 

Lender Borrower Address Date Amount
Chris Camarsh, Moss Ridge PTY Ltd. Gardiner Founder LLC [***] 1-Jan-20 $300,000
Gardiner Warrant Holdings LLC (CHARDAN) Gardiner Healthcare Acquisitions Corp. [***]

24-Mar-23

$14,190.00

Chris Camarsh, Moss Ridge PTY Ltd. Gardiner Healthcare Acquisitions Corp. [***] 23-Mar-23 $534,723.45
Anthony Julian, Sera Australia PTY LTD ATF Serani Hybrid Trust Gardiner Healthcare Acquisitions Corp. [***] 24-Mar-23 $14,636.00
Chris Camarsh, Moss Ridge PTY LTD Gardiner Healthcare Acquisitions Corp. [***] 31-Mar-23 $167,000.00
Chris Camarsh, Moss Ridge PTY LTD Gardiner Healthcare Acquisitions Corp. [***] 17-Apr-23 $30,000.00
Chris Camarsh, Seisun Capital PTY LTD Gardiner Healthcare Acquisitions Corp. [***] 26-Apr-23 $75,000.00
Guy Spriggs Trust 12/16 Gardiner Healthcare Acquisitions Corp. [***] 27-Apr-23 $200,000
Virginia Stack (Gerald Stack) Gardiner Healthcare Acquisitions Corp. [***] 28-Apr-23 $75,000
Kent Rinker Gardiner Healthcare Acquisitions Corp. [***] 22-Feb-23 $50,000
Greg Sukenik Gardiner Healthcare Acquisitions Corp. [***] 24-Feb-23 $25,000

 

- 15 -

 EX-101.SCH 3 tmb-20230629.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 tmb-20230629_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 tmb-20230629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member] Shares of common stock, par value $0.0001 per share, included as part of the units [Member] Redeemable warrants included as part of the units [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Redeemable warrants included as part of the units Shares of common stock, par value $0.0001 per share, included as part of the units Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant EX-101.PRE 6 tmb-20230629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 29, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 29, 2023
Entity File Number 001-41185
Entity Registrant Name GARDINER HEALTHCARE ACQUISITIONS CORP.
Entity Central Index Key 0001858912
Entity Tax Identification Number 86-2899992
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3107 Warrington Road
Entity Address, City or Town Shaker Heights
Entity Address, State or Province OH
Entity Address, Postal Zip Code 44120
City Area Code 216
Local Phone Number 633-6708
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant
Trading Symbol GDNRU
Security Exchange Name NASDAQ
Shares of common stock, par value $0.0001 per share, included as part of the units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Shares of common stock, par value $0.0001 per share
Trading Symbol GDNR
Security Exchange Name NASDAQ
Redeemable warrants included as part of the units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants
Trading Symbol GDNRW
Security Exchange Name NASDAQ
XML 8 tm2320673d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001858912 2023-06-29 2023-06-29 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-06-29 2023-06-29 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-06-29 2023-06-29 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-06-29 2023-06-29 iso4217:USD shares iso4217:USD shares 0001858912 false 8-K 2023-06-29 GARDINER HEALTHCARE ACQUISITIONS CORP. DE 001-41185 86-2899992 3107 Warrington Road Shaker Heights OH 44120 216 633-6708 false false false false Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant GDNRU NASDAQ Shares of common stock, par value $0.0001 per share GDNR NASDAQ Redeemable warrants GDNRW NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gardinerhealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2320673d1_8k.htm tm2320673d1_ex10-1.htm tmb-20230629.xsd tmb-20230629_def.xml tmb-20230629_lab.xml tmb-20230629_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2320673d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "tmb-20230629_def.xml" ] }, "inline": { "local": [ "tm2320673d1_8k.htm" ] }, "labelLink": { "local": [ "tmb-20230629_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230629_pre.xml" ] }, "schema": { "local": [ "tmb-20230629.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 3, "memberStandard": 0, "nsprefix": "tmb", "nsuri": "http://gardinerhealthcare.com/20230629", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2320673d1_8k.htm", "contextRef": "AsOf2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://gardinerhealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2320673d1_8k.htm", "contextRef": "AsOf2023-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "tmb_RedeemableWarrantsIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants included as part of the units", "label": "Redeemable warrants included as part of the units [Member]" } } }, "localname": "RedeemableWarrantsIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230629", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock, par value $0.0001 per share, included as part of the units", "label": "Shares of common stock, par value $0.0001 per share, included as part of the units [Member]" } } }, "localname": "SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230629", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant", "label": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember", "nsuri": "http://gardinerhealthcare.com/20230629", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-078771-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-078771-xbrl.zip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�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end